Day: February 14, 2024

MIGDAL HAEMEK, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the fourth quarter and for the year ended December 31, 2023. Fourth Quarter of 2023 Results Overview Revenue for the fourth quarter of 2023 was $352 million as compared with $358 million for the third quarter of 2023. Revenue for the fourth quarter of 2022 was $403 million. Gross profit for the fourth quarter of 2023 was $84 million as compared with $87 million for the third quarter of 2023. Gross profit for the fourth quarter of 2022 was $125 million. Operating profit for the fourth quarter of 2023 was $45 million, as compared with $362 million in the third quarter of 2023 which included $314 million, net, from the Intel merger contract termination. Operating profit for the fourth quarter...

Fourth quarter revenues of $56.6 million, in line with previous guidance Fourth quarter GAAP net loss of $22.9 million; non-GAAP net income of $3.8 million Achieved breakeven adjusted EBITDA and generated positive operating cash flow for the fourth quarter Successfully launched the Apollo platform for general commercial use in early 2024 Expecting modest revenue growth, adjusted EBITDA profitability, and positive operating cash flow for the full year 2024ROSH-HA`AYIN, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a worldwide market leader in sustainable, on-demand, digital fashionX and textile production technologies, reported today its results for the fourth quarter and full year ended December 31, 2023. “We experienced a healthy peak season, with year-over-year growth...

NORCROSS, Ga., Feb. 14, 2024 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD) (“CoreCard” or “the Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter and full year ended December 31, 2023. “Overall revenue of $12.2 million in the fourth quarter was in-line with our expectations, reflecting continued year-over-year growth in processing and maintenance revenue of 8%, which was offset by lower professional services revenue, primarily driven by our largest customer. Additionally, our full year processing and maintenance revenue grew by 18% compared to full year 2022,” said Leland Strange, CEO of CoreCard Corporation. “We continue to invest in our platform and processing capabilities,...

With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint inhibitor therapies, while maintaining an acceptable safety profile Tumor shrinkage was also observed in all high-dose phase-2 eligible patients with stable disease (SD). In addition to a new PR, the clinical benefit rate (PR plus SD for over 24 weeks) and tumor control rate (PR plus all SD) increased to 46% and 69%, respectively First patient was dosed in Phase 1 combination escalation portion of the ABILITY Study evaluating MDNA11 with KEYTRUDA® (pembrolizumab) Additional monotherapy data updates and preliminary combination escalation and expansion data to be shared in H1 and H2 of 2024 Cash runway extended through multiple data readouts and...

Record Revenues of $8.4 million and Record Net Income of $2.5 million MISSISSAUGA, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2024 ended December 31, 2023 (“Q1”), with record quarterly revenues and a record quarterly profit, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices, and material licensing revenues from its fully-funded program to revalidate and relaunch its approved drug, Kinlytic® urokinase (“Kinlytic”). Management DiscussionResults for Q1 demonstrate strong growth in sales of each of Microbix’s test ingredients (“Antigens”) and its test quality assessment products (“QAPs™”), which were collectively...

Record Fourth Quarter Financial HighlightsRevenue of $1.5 billion increases 35% year-over-year Organic revenue growth of 34% including at least 20% organic growth in both segments for the third consecutive quarter Net income of $45 million increases 60% Adjusted EBITDA of $128 million increases 30% year-over-year Cash flow from operations of $190 million Contract awards increase 13% year-over-year to $1.2 billionRecord Fiscal Year 2023 HighlightsRevenue of $5.4 billion, representing total growth of 30% and organic growth of 23% Net income of $161 million increases 67% Adjusted EBITDA of $465 million increases 32% year-over-year Cash flow from operations increases 72% to $408 million Contract awards of $6.0 billion increases 40%; trailing 12-month book-to-bill ratio of 1.1x Won 15 contracts each worth $100 million or more Establishing...